Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2002-10-25
2003-09-30
Reamer, James H (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
06627602
ABSTRACT:
TECHNICAL FIELD
The invention herein is directed to prevention of desensitization of receptors to activation by agonists. BACKGROUND OF THE INVENTION
Many receptors which are involved in controlling pathologic conditions are coupled to G-proteins (Pierce, K. L., et al, Nature Review (Molecular Cell Biology) 3, 639-650 (2002)). These are called G-protein coupled receptors (GPCRs). The GPCRs include &agr;-adrenergic receptors, &bgr;-adrenergic receptors, opioid receptors and prostaglandin receptors. Over time, when agonists are administered to activate the receptors, the receptors become desensitized, i.e., agonist administration no longer results in therapeutic activation of receptors and the receptors regardless of agonist administration are unable to control the pathologic condition.
SUMMARY OF THE INVENTION
It is known that when agonist binds to a GPCR to activate it, the sequence of events is that the receptor is phosphorylated, the phosphorylated receptor moves to the interior of the cell it is associated with, i.e., it is internalized, with the internalization often involving recruitment of &bgr;-arrestin and then the receptor is recycled and moves to the surface of the cell housing it where it is available to control a disease event and to bind to agonist for activation for control of the disease event. The GPCRs have G-protein receptor kinases (GRKs) associated with them. The GRKs phosphorylate agonist-occupied receptors thereby promoting binding of &bgr;-arrestin molecules which inhibit interactions between the receptors and G-proteins while also promoting internalization of the receptors. GRKs thus dampen signaling by the GPCRs. The typical response is decreased level of GPCRs and desensitization thereof (i.e., inability of agonist to activate the receptor and inability of the GPCRs to control the disease event). It has been discovered herein that nitric oxide donors (NO donors) that donate nitric oxide or a related redox species and provide bioactivity that is identified with nitric oxide, preferably S-nitrosoglutathione (GSNO), inhibit the GRKs dramatically thereby allowing GPCRs to signal and to be recycled to the cell surface, i.e., thus preventing desensitization of the GPCRs and allowing GPCRs to be available in sufficient amount to control the disease event. It has also been discovered herein that administration of GSNO results in growth of heart muscle (hypertrophy) in vivo (which can be both dependent and independent of expression of receptors) and prevents cardiac &bgr;-adrenergic receptor down regulation after chronic administration of a &bgr;-adrenergic agonist.
The above discoveries support the invention herein which is directed to a method for treating a patient with a disease or pathologic condition associated with G-protein receptor kinase activity where the G-protein receptor kinase activity would otherwise cause desensitization of a receptor controlling said disease or condition, said method comprising the step of administering NO donor that donates nitric oxide or a related redox species and provides bioactivity that is identified with nitric oxide to inhibit the G-protein receptor kinase activity, thereby sensitizing or preventing desensitization of said receptor.
The term “disease or condition associated with G-protein receptor kinase activity” is used herein to mean a disease or condition resulting from under-stimulation of a GPCR or related insufficient activation of a GPCR.
G-protein receptor kinase activity is described in Pierce, et al, cited above.
The term “controlling said disease or condition” is used herein to mean influence the biochemical or clinical correlate of the disease or condition.
The term “desensitization of a receptor” is used herein to mean decreased activity or decreased level of expression or decreased responsiveness.
The term “to inhibit the G-protein receptor kinase activity” is used herein to mean to decrease its activity.
REFERENCES:
patent: 5574068 (1996-11-01), Stamler et al.
patent: 5968911 (1999-10-01), Lawson et al.
patent: 5985862 (1999-11-01), Tjoeng et al.
patent: 6139847 (2000-10-01), Chobanian et al.
patent: 6297260 (2001-10-01), Bandarage et al.
patent: 6472390 (2002-10-01), Stamler et al.
patent: 6482846 (2002-11-01), Garvey et al.
patent: 6486206 (2002-11-01), Lurie
patent: 2001/0012834 (2001-08-01), Stamler
patent: 2002/0010146 (2002-01-01), Garvey et al.
patent: WO 02/32418 (2002-04-01), None
Koch Walter J.
Lefkowitz Robert J.
Piantadosi Claude A.
Stamler Jonathan S.
Whalen Erin J.
Duke University
Reamer James H
LandOfFree
Preventing desensitization of receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preventing desensitization of receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preventing desensitization of receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3061346